The present invention relates to the discovery of markers for
neurodegenerative disease. More particularly, it was discovered that
forms of IRP-2 protein that are unable to undergo oxidation at critical
cysteine residues are diagnostic for neurodegenerative disease including,
but not limited to Alzheimer's disease. Embodiments include nucleic acids
that encode mutant IRP-2 proteins and fragments thereof, mutant IRP-2
proteins and fragments thereof, antibodies directed to epitopes present
on mutant IRP-2 proteins and fragments thereof, methods of making these
nucleic acids and polypeptides, as well as, approaches to diagnose
neurodegenerative disease in animals, such as humans at risk of
contracting Alzheimer's disease.